Aurobindo Pharma Likely to Clinch Mallinckrodt Deal for USD 800 Million this July

Even as Hyderabad-based drug major Aurobindo Pharma is gearing up to acquire UK-based Mallinckrodt’s specialty generics business in the US for an estimated USD 800 million (one of the largest outbound buys by a homegrown pharma firm), the street is cautious as it is a declining business, and lot depends on Aurobindo’s ability to turn it around. The homegrown drug major has already approached bankers to raise debt to clinch the deal which is likely to be signed within this month, said sources close to the development. An email sent to Aurobindo, however, did not receive any immediate response. The company’s stock was down 0.95 percent to ₹617.25 a piece on BSE on Tuesday. Mallinckrodt has a diverse portfolio of medicinal controlled substances and what makes it a lucrative target is it received over 30 percent of the US Drug Enforcement Administration (DEA) quota for manufacturing-controlled substances in the US last year. A controlled substance is generally a drug or chemical whose manufacture, possession, or use is regulated by a government. The entry barrier in this segment is thus quite high.

A source who is tracking the deal closely said, “The best part of the deal this deal enables Aurobindo break the entry barrier (the manufacturing quota etc.) for a niche portfolio that would have taken them 10 years to achieve organically.” The deal will include two manufacturing facilities. Controlled substances constitute around 5 percent of Aurobindo’s US revenues at present, and some think that the acquisition is a strategic fit to grow the same line of business. The controlled substances business in US generates an EBITDA of USD 40 million for Aurobindo, sources revealed. Meanwhile, Trump administration’s crackdown on opioid addition has led to increased scrutiny of drug makers who handle such a portfolio. “There are more than 500 lawsuits which are currently going on in courts against the company due to opioid misuse. There were 42,000 deaths in US alone due to opioid misuse in 2016. Key reasons for this is over subscription and abuse of painkillers. It is a sort of crisis in the US for opioid misuse and government is actively looking to reduce the opioid use and prescription,” Edelweiss said.

This raises the risks of legal battles. “The Mallinckrodt portfolio that Aurobindo is looking to buy is a generic one and does not have any branded product. Therefore, there is no promotion by the company, which, in turn, may lead to scrutiny of the drug maker inducing opioid addiction. Rather, for most of these drugs, there is no substitute and the manufacturing will never stop as they are the only source of pain relief in many terminal illnesses,” revealed the source who is working on the deal. Regulatory challenges, however, have pushed down the valuation of the portfolio. Mallinckrodt had expected to fetch around USD 2 billion for the generics business when it put it on the block in March 2017. Sources claim that Aurobindo is likely to lap it up now for USD 800 million. The portfolio which has an annual sale of around USD 732 million, this converts to a little more than 1X of sales. Edelweiss, however, claimed that the business has declined by 25 percent in the last one and a half years, and current margins are around 21.6 percent.

“Aurobindo has an EBITDA of around USD 600-650 million, and debt of around USD 500 million. Post-acquisition (assuming it raises the entire USD 800 million in debt), the balance sheet is thus not highly leveraged,” said the source who also claimed the margins for the portfolio were around 30 percent or so. A Mumbai-based analyst who tracks the pharma firm said that while there is room for growth in this niche segment, a lot depends on how Aurobindo builds on the efficiency parameters. “It cannot shift the manufacturing to India as in case of other generics to boost margins immediately. Manufacturing of controlled substances is closely monitored in the US,” he added. As such the US generic business of Aurobindo is facing pricing pressure – the price erosion was around 8 percent year-on-year for Q4FY18. It is the fifth largest generic pharma company in the US by prescription value dispensed.

• Around 5 percent of Aurobindo’s US biz comes from controlled substances.
• Controlled substances generate an EBITDA of USD 40 million.
• It has 16 ANDAs in the controlled substances in the US.
• Manufacturing of controlled substances is closely monitored by US government.
• Mallinckrodt received over 30 percent USDEA quota for manufacturing-controlled substances in 2017.
• More than 500 law suits going on against Mallinckrodt for opioid misuse.
• Trump administration crackdown on opioid addiction is likely to raise legal risks.
• Sources say target portfolio does not have branded drugs, hence legal risks low.
• Intas Pharma had backed out of the deal early this year.
• Regulatory fear has eroded valuation of Mallinckrodt’s business. – Business Standard